{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    8,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "a",
        "name": "Amendment a",
        "scope": {
          "id": "30f404cf-8889-4c8a-a64d-ade41514dfef",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "da98b1e1-8f8b-43b6-bd2d-4fc46fb55bf0",
          "code": {
            "id": "8fa795b9-752b-4293-937f-4dd25f7064c1",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "822afea7-e312-466d-b7e7-2ca3817eff25",
            "type": {
              "id": "5e32ed0d-febc-4613-8460-13a2109542bd",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment (a) was electronically signed and approved by Lilly on 28 Sep 2018.",
        "effectiveDate": "2018-09-28",
        "reasonIds": [
          "ar_1_1"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "a"
      },
      {
        "id": "amend_2",
        "number": "b",
        "name": "Amendment b",
        "scope": {
          "id": "de78de83-ea52-4d0b-b755-6600f4ab8332",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "5a853d3c-fcca-49c3-b6f1-a15dea7839dd",
          "code": {
            "id": "77d68295-b6c5-4d9d-847e-7f8e304207a3",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "a506c673-dd90-4323-90e5-c75d854304cd",
            "type": {
              "id": "1509a9cc-c449-464c-b696-e791fed717f8",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main reason for preparation of this amendment was to incorporate changes to study procedures due to the COVID-19 pandemic, as detailed in Appendix 8, and to update the protocol for continued efficacy and safety assessment of LY3298176.",
        "effectiveDate": "2020-07-10",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "a",
        "newVersion": "b"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 0,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope"
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "Original Protocol",
        "effectiveDate": "2018-07-18",
        "summary": "Initial release of the protocol for the SURPASS-4 study evaluating LY3298176 versus Insulin Glargine in patients with Type 2 Diabetes and increased cardiovascular risk.",
        "previousVersion": null,
        "newVersion": "Original",
        "reasons": [
          "Scientific"
        ]
      },
      {
        "number": "a",
        "effectiveDate": "2018-09-28",
        "summary": "Amendment (a) was electronically signed and approved by Lilly on 28 Sep 2018.",
        "previousVersion": "Original Protocol",
        "newVersion": "a",
        "reasons": [
          "Administrative"
        ]
      },
      {
        "number": "b",
        "effectiveDate": "2020-07-10",
        "summary": "The main reason for preparation of this amendment was to incorporate changes to study procedures due to the COVID-19 pandemic, as detailed in Appendix 8, and to update the protocol for continued efficacy and safety assessment of LY3298176.",
        "previousVersion": "a",
        "newVersion": "b",
        "reasons": [
          "Operational",
          "Regulatory",
          "Safety"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [],
      "regions": [],
      "plannedSites": null
    },
    "sites": []
  }
}